PDCD1 and colorectal carcinoma: Only in 2017, the FDA granted accelerated approval for the first two PD-1 monoclonal antibodies (moAbs) to treat MSI-H or dMMR CRC: Opdivo, also known as nivolumab, MDX-1106, BMS-936558, and ONO-4538 (Bristol-Myers Squibb) and Keytruda, also known as pembrolizumab, lambrolizumab, and MK-3475 (Merck) [125] (Figure 2).